First, do no harm, second, do some good, third, give choice and fourth, save cash: the 1, 2, 3 and 4 of transdermal oestradiol as androgen deprivation therapy ticks all the boxes

Abstract

Tripodi has stated that the widely held and promoted notion that laboratory monitoring is not required for patients treated with non-vitamin K antagonist oral anticoagulants has been overemphasised, potentially leading clinicians to believe that laboratory testing is not needed for these patients. 4 Our data support Tripodi's viewpoint. Other potential reasons for our findings include greater familiarity with warfarin than dabigatran and uncertainty in the interpretation of coagulation test results with dabigatran. Management guidelines that utilise these tests, for both thromboembolic and haemorrhagic events, have been proposed. 5,6 Studies assessing clinical outcomes from using these guidelines will be valuable in informing practice in this area of uncertainty.